Pamnani Harsha, Jindal Radhika, Khare Jaideep, Sharma Monika, Siddiqui Asim, Wangnoo Subhash K
Department of Endocrinology, Peoples College of Medical Sciences and Research Centre, Bhopal, Madhya Pradesh, India.
Department of Endocrinology, Safdarjung Hospital, New Delhi, India.
Indian J Endocrinol Metab. 2022 Mar-Apr;26(2):149-153. doi: 10.4103/ijem.ijem_29_22. Epub 2022 Jun 6.
Radio-active Iodine (RAI) is a safe, definitive, and cost-effective modality of treatment that is used as the first line of treatment for Graves' hyperthyroidism by most endocrinologists. Very few reports are available from India, observational follow-up data is needed to determine the meaningful prognostic outcomes of RAI ablation in the Indian population.
To study the outcomes in hyperthyroid patients undergoing RAI ablation.
This observational cohort study was conducted at Department of Endocrinology at Indraprastha Apollo Hospital, New Delhi. A total of 82 hyperthyroid patients who underwent RAI ablation between June 2014 to June 2018 were enrolled. RAI dose was calculated arbitrarily in most cases; often by an empirical fixed dose based on the goiter size and RAIU. The patients were reviewed at 1, 3 and 6 months post-RAI ablation. During follow-up, along with a detailed clinical examination, free T4, free T3 and TSH were checked.
The dose of I-131 varied from 6 mCi to 14 mCi. Most of the patients were given RAI in the dose of 7.1-10 mci. About 63.4% of patients achieved hypothyroidism in 6 months, 6.1% in 1 month, 37.8% in 3 months, and 19.5% in 6 months. Gender, age, etiology of hyperthyroidism, baseline thyroid function, goiter, and ophthalmopathy did not affect outcomes after RAI ablation. Those who were not treated with antithyroid drugs prior to RAI therapy were found to have higher rates of conversion to a hypothyroid state.
RAI can be given safely as the first line of treatment in Graves' disease and antithyroid drug naïve patients respond better to therapy.
放射性碘（RAI）是一种安全、有效的确定性治疗方式，且具有成本效益，大多数内分泌学家将其用作格雷夫斯甲亢的一线治疗方法。印度的相关报告极少，需要观察性随访数据来确定RAI消融在印度人群中的有意义的预后结果。
研究接受RAI消融的甲亢患者的治疗结果。
本观察性队列研究在新德里英迪拉·普拉萨德·阿波罗医院内分泌科进行。共纳入了2014年6月至2018年6月期间接受RAI消融的82例甲亢患者。在大多数情况下，RAI剂量是任意计算的；通常根据甲状腺肿大小和RAIU采用经验性固定剂量。在RAI消融后1个月、3个月和6个月对患者进行复查。随访期间，除了进行详细的临床检查外，还检查了游离T4、游离T3和TSH。
I-131剂量从6毫居里到14毫居里不等。大多数患者接受的RAI剂量为7.1 - 10毫居里。约63.4%的患者在6个月时出现甲状腺功能减退，1个月时为6.1%，3个月时为37.8%，6个月时为19.5%。性别、年龄、甲亢病因、基线甲状腺功能、甲状腺肿和眼病均不影响RAI消融后的治疗结果。发现那些在RAI治疗前未接受抗甲状腺药物治疗的患者转化为甲状腺功能减退状态的比例更高。
RAI可安全地作为格雷夫斯病的一线治疗方法，且未使用过抗甲状腺药物的患者对治疗反应更好。
